Growth hormone treatment for growth failure in pediatric patients with Crohn's disease.

OBJECTIVE To investigate the effect of human growth hormone (GH) injections on growth velocity in growth-impaired children with Crohn's disease (CD). STUDY DESIGN Ten children and adolescents (mean age, 12.6 +/- 4.5 years; 6 males) with CD and poor height growth were treated with open-label recombinant GH, 0.043 mg/kg/day administered via subcutaneous injection, for 1 year. Patients were retrospectively matched with untreated patients (3 comparisons per case) by race, age, sex, and baseline height. Primary endpoint was height velocity; secondary endpoints were disease activity, body composition, and bone density determined by dual-energy x-ray absorptiometry scan. RESULTS Mean height velocity increased by 5.33 +/- 3.40 (mean +/- standard deviation) cm/year in the GH-treated patients during the year of GH treatment, compared with 0.96 +/- 3.52 cm/year in the comparison group (P = .03). Height z-score increased by 0.76 +/- 0.38 in the treated group, compared with 0.16 +/- 0.40 in the comparison group (P < .01), and weight z-score increased by 0.81 +/- 0.89 in the treated group, compared with 0.00 +/- 0.57 in the comparison group (P < .01). Bone density revealed an increase of 0.31 +/- 0.33 in the lumbar spine z-score (P = .03 vs baseline). CONCLUSIONS GH treatment increases height velocity and may enhance bone mineralization in children with CD. A randomized controlled trial in a large cohort of children is needed to evaluate the ultimate impact of GH treatment.

[1]  R. Baldassano,et al.  Inflammatory bowel disease in pediatric and adolescent patients. , 1999, Gastroenterology clinics of North America.

[2]  B. Kirschner,et al.  Bone mineral density assessment in children with inflammatory bowel disease. , 1998, Gastroenterology.

[3]  J. Markowitz,et al.  Growth failure in pediatric inflammatory bowel disease. , 1993, Journal of pediatric gastroenterology and nutrition.

[4]  F. Dunstan,et al.  Inflammatory bowel disease and predisposition to osteopenia , 1997, Archives of disease in childhood.

[5]  R. Baldassano,et al.  Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. , 2005, The Journal of pediatrics.

[6]  A. Sadeghi‐Nejad,et al.  Effect of Recombinant Growth Hormone Treatment on Children With Crohn's Disease and Short Stature: A Pilot Study , 2005, Inflammatory bowel diseases.

[7]  D. Milov,et al.  Growth hormone has anabolic effects in glucocorticosteroid-dependent children with inflammatory bowel disease: a pilot study. , 2002, Metabolism: clinical and experimental.

[8]  J. Henker Therapy with recombinant growth hormone in children with Crohn disease and growth failure , 1996, European Journal of Pediatrics.

[9]  J. H. MacMillan,et al.  Growth and clinical course of children with Crohn's disease. , 1993, Gut.

[10]  F. Glorieux,et al.  Interpretation of Bone Mineral Density Values in Pediatric Crohn's Disease , 1998, Inflammatory bowel diseases.

[11]  J. Burnham,et al.  Whole Body BMC in Pediatric Crohn Disease: Independent Effects of Altered Growth, Maturation, and Body Composition , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  R. Baldassano,et al.  Risk factors for initial surgery in pediatric patients with Crohn's disease. , 2006, Gastroenterology.

[13]  M. Corey,et al.  Assessing activity of pediatric Crohn's disease: which index to use? , 1999, Gastroenterology.

[14]  J. Kirsner,et al.  Effect of administered human growth hormone on growth retardation in inflammatory bowel disease , 1974, The American Journal of Digestive Diseases.

[15]  A. Griffiths,et al.  Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. , 2007, Gastroenterology.

[16]  M. Savage,et al.  Clinical Features Affecting Final Adult Height in Patients With Pediatric-Onset Crohn's Disease , 2006, Pediatrics.

[17]  L. Ellegård,et al.  Low-dose recombinant human growth hormone increases body weight and lean body mass in patients with short bowel syndrome. , 1997, Annals of surgery.

[18]  I. Booth The Nutritional Consequences of Gastrointestinal Disease in Adolescence , 1991, Acta paediatrica Scandinavica. Supplement.

[19]  T. Bayless,et al.  Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease. , 1988, Gastroenterology.

[20]  R. Prince,et al.  A Double-Blind Placebo-Controlled Study of the Effects of the Bisphosphonate Risedronate on Bone Mass in Patients with Inflammatory Bowel Disease , 2006, The American Journal of Gastroenterology.

[21]  A. Griffiths,et al.  Relationship of Common Laboratory Parameters to the Activity of Crohn's Disease in Children , 1992, Journal of pediatric gastroenterology and nutrition.

[22]  P. Czernichow,et al.  Growth in Paediatric Crohn’s Disease , 2002, Hormone Research in Paediatrics.

[23]  M. Mckinley,et al.  A preliminary study of growth hormone therapy for Crohn's disease. , 2000, The New England journal of medicine.

[24]  A. Jawad,et al.  Risk factors for low bone mineral density in children and young adults with Crohn's disease. , 1999, The Journal of pediatrics.

[25]  K. Motil,et al.  Growth failure in children with inflammatory bowel disease: a prospective study. , 1993, Gastroenterology.